Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cellsin a HIF-1α-dependent manner

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2005-2012

  Yamada, Naoko ^a   Yamanegi, Koji ^a   Ohyama, Hideki ^a   Hata, Masaki ^a   Nakasho, Keiji ^a   Futani, Hiroyuki ^a   Okamura, Haruki ^a   Terada, Nobuyuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Hypoxia; Hypoxia inducing factor 1 ; MHC class I related chain molecule; Nitric oxide; Osteosarcoma; Soluble MHC class I related chain molecule A

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; HLA A ANTIGEN; HLA B ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NATURAL KILLER CELL RECEPTOR NKG2D; NITRATE; NITRIC OXIDE; NITRITE; PROTEIN; SMALL INTERFERING RNA; UL16 BINDING PROTEIN 1; UL16 BINDING PROTEIN 2; UL16 BINDING PROTEIN 3; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; HYPOXIA; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION;

CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KILLER CELLS, NATURAL; LIGANDS; NITRIC OXIDE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OSTEOSARCOMA;

EID: 84869765082     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1630     Document Type: Article

References (26)

1. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M and Noman MZ: Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 3: 1-10, 2012.
2. Wilson WR and Hay MP: Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410, 2011.
3. Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001. (Pubitemid 32219813)
4. Melillo G: Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol Cancer Res 4: 601-605, 2006.
5. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003.
6. Semenza GL: Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med 41: 79-83, 2002.
7. Giaccia A, Siim BG and Johnson RS: HIF-1 as a target for drug development. Nat Rev Drug Discov 2: 803-811, 2003. (Pubitemid 37361812)
8. Waldhauer I and Steinle A: NK cells and cancer immunosurveillance. Oncogene 27: 5932-5943, 2008.
9. Nausch N and Cerwenka A: NKG2D ligands in tumor immunity. Oncogene 27: 5944-5958, 2008.
10. Salih HR, Rammensee H-G and Steinle A: Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169: 4098-4102, 2002. (Pubitemid 35178177)
11. Salih HR, Goehlsdorf D and Steinle A: Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol 67: 188-195, 2006. (Pubitemid 43673929)
12. Waldhauer I and Steinle A: Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res 66: 2520-2526, 2006.
13. Boutet P, Agüera-González S, Atkinson S, Pennington CJ, Edwards DR, Murphy G, Reyburn HT and Valés-Gómez M: Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol 182: 49-53, 2009.
14. Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419: 734-738, 2002. (Pubitemid 35177960)
15. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S and Pistoia V: Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia 6: 558-568, 2004. (Pubitemid 39411093)
16. Märten A, von Lilienfeld-Toal M, Büchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing γδT cell cytotoxicity. Int J Cancer 119: 2359-2365, 2006. (Pubitemid 44546956)
17. Lee CT, Mace T and Repasky EA: Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer? Int J Hyperthermia 26: 232-246, 2010.
18. Siemens DR, Hu N, Sheikhi AK, Chung E, Frederiksen LJ, Pross H and Graham CH: Hypoxia increases tumor cell shedding of MHC class I chain-related molecule: role of nitric oxide. Cancer Res 68: 4746-4753, 2008.
19. Barsoum IB, Hamilton TK, Li X, Cotechini T, Miles EA, Siemens DR and Graham CH: Hypoxia induces escape from innate immunity in cancer cells via increased expression of ADAM10: role of nitric oxide. Cancer Res 71: 7433-7441, 2011.
20. Postovit LM, Adams MA, Lash GE, Heaton JP and Graham CH: Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. J Biol Chem 277: 35730-35737, 2002.
21. Postovit LM, Sullivan R, Adams MA and Graham CH: Nitric oxide signalling and cellular adaptations to changes in oxygenation. Toxicology 208: 235-248, 2005. (Pubitemid 40187334)
22. Postovit LM, Adams MA, Lash GE, Heaton JP and Graham CH: Nitric oxide-mediated regulation of hypoxia-induced B16F10 melanoma metastasis. Int J Cancer 108: 47-53, 2004. (Pubitemid 37444442)
23. Yoon SY, Lee YJ, Seo JH, Sung HJ, Park KH, Choi IK, Kim SJ, Oh SC, Choi CW, Kim BS, Shin SW, Kim YH and Kim JS: uPAR expression under hypoxic conditions depends on iNOS modulated ERK phosphorylation in the MDA-MB-231 breast carcinoma cell line. Cell Res 16: 75-81, 2006.
24. Quintero M, Brennan PA, Thomas GJ and Moncada S: Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1alpha in cancer: role of free radical formation. Cancer Res 66: 770-774, 2006. (Pubitemid 43165941)
25. Luo L, Lu J, Wei L, Long D, Guo JY, Shan J, Li FS, Lu PY, Li PY and Feng L: The role of HIF-1 in up-regulating MICA expression on human renal proximal tubular epithelial cells during hypoxia/reoxygenation. BMC Cell Biol 11: 1-13, 2010.
26. Wei L, Lu J, Feng L, Long D, Shan J, Li S and Li Y: HIF-1alpha accumulation upregulates MICA and MICB expression on human cardiomyocytes and enhances NK cell cytotoxicity during hypoxia-reoxygenation. Life Sci 87: 111-119, 2010.